Pioglitazone

Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026

Pioglitazone is an oral thiazolidinedione used with diet and exercise to improve glycemic control in adults with type 2 diabetes. It improves insulin sensitivity but can cause fluid retention, weight gain, heart failure exacerbation, edema, bone fracture risk, and macular edema. It is not used for type 1 diabetes or diabetic ketoacidosis.

Exploratory record, not a reviewed medical publication.

See the editorial and medical-review policies for the publication gate.

This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.

In short

What the research says.

A quick, data-only summary. The full evidence, dosing, and sources are below.

Pioglitazone is an oral thiazolidinedione used with diet and exercise to improve glycemic control in adults with type 2 diabetes. NutriStack rates the supporting evidence as strong. Common adult dosing is 15-45 mg orally once daily, individualized by glycemic response and tolerability, though a prescriber sets the actual dose. This profile indexes 3 sources.

What it's good for

Improves glycemic control in type 2 diabetes²
Improves insulin sensitivity¹
Can improve some triglyceride and HDL patterns
May help selected patients with insulin resistance when benefits outweigh risks¹

What to watch for

Edema and fluid retention
Weight gain
Congestive heart failure exacerbation
Initiation in NYHA class III or IV heart failure^2,3
Hypersensitivity to pioglitazone^1,2

The bottom line

Evidence rating strong. Most-documented uses: improves glycemic control in type 2 diabetes, improves insulin sensitivity, can improve some triglyceride and hdl patterns. 3 sources indexed (2005–2025), with 0 interaction records on file.

The science

How it works, mechanistically.

Core mechanism

Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), changing transcription of insulin-responsive genes in adipose tissue, skeletal muscle, and liver. This improves peripheral insulin sensitivity and reduces hepatic glucose output but also promotes adipocyte differentiation and sodium/fluid retention, explaining weight gain and edema. Bone effects are clinically relevant because thiazolidinediones increase fracture risk, particularly in women.^1,2

Class

Thiazolidinedione insulin sensitizer

Dosing

Dosing & protocol.

Common range

15-45 mg orally once daily, individualized by glycemic response and tolerability

Recommended form

Oral tablet once daily

May be taken with or without food. Clinical effect develops gradually over weeks.

Safety

Full safety detail.

Side effects

Edema and fluid retention
Weight gain
Congestive heart failure exacerbation
Hypoglycemia when combined with insulin or secretagogues
Bone fracture risk
Macular edema
Upper respiratory infection
Possible bladder cancer warning with prolonged exposure

Contraindications

Initiation in NYHA class III or IV heart failure^2,3
Hypersensitivity to pioglitazone^1,2
Active bladder cancer or unexplained hematuria without evaluation³
Type 1 diabetes or diabetic ketoacidosis²
Use with caution in liver disease, edema, heart failure risk, osteoporosis, or macular edema^1,2

Sources

Sources, by evidence tier.

Numbered references. Citations throughout the page link here.

Randomized controlled trials

1Pioglitazone after Ischemic Stroke or Transient Ischemic AttackKernan WN et al. · New England Journal of Medicine · 2016
Pioglitazone lowered recurrent stroke or MI risk but increased weight gain, edema, and fracture.
2Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive StudyDormandy JA et al. · Lancet · 2005
Pioglitazone affected secondary macrovascular endpoints but increased edema and heart failure events.

Reference material

3Pioglitazone tablets US prescribing informationUS Food and Drug Administration · DailyMed FDA Label · 2025
Label describes CHF boxed warning, dosing, edema, fractures, bladder tumor warning, and monitoring.

FAQ

Common questions.

Quick answers about Pioglitazone, drawn from the data on this page.

What is Pioglitazone?

What is Pioglitazone used for?

Commonly cited benefits of Pioglitazone include: Improves glycemic control in type 2 diabetes; Improves insulin sensitivity; Can improve some triglyceride and HDL patterns; May help selected patients with insulin resistance when benefits outweigh risks. NutriStack rates the overall evidence as strong.

What is a typical dose of Pioglitazone?

A typical adult dose of Pioglitazone is 15-45 mg orally once daily, individualized by glycemic response and tolerability. The commonly recommended form is Oral tablet once daily. These are general ranges, not personalized advice; confirm the right dose with a clinician.

What are the side effects of Pioglitazone?

Reported side effects include edema and fluid retention, weight gain, congestive heart failure exacerbation, hypoglycemia when combined with insulin or secretagogues, bone fracture risk, macular edema. This is educational information; check with a healthcare professional before use.

How strong is the evidence for Pioglitazone?

NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.

Use this with your stack

Pioglitazone in NutriStack.

Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.

Download on the App Store → Read the methodology